Trial Profile
Multicenter clinical study of anti-VEGF treatment on high risk diabetic retinopathy
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- 03 Nov 2016 New trial record